Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2'-deoxycytidine.
D001374:Azacitidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D002478:Cells, Cultured; D003561:Cytarabine / Q000494:pharmacology*; D003570:Cytidine Triphosphate / Q000031:analogs & derivatives* / Q000494:pharmacology; D003597:Cytosine Nucleotides; D005786:Gene Expression Regulation / Q000187:drug effects*; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II / Q000235:genetics*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000276:immunology*
D003597:Cytosine Nucleotides; D006684:HLA-DR Antigens; D000949:Histocompatibility Antigens Class II; D003561:Cytarabine; D003570:Cytidine Triphosphate; C038673:5-aza-2'-deoxycytidine-5'-triphosphate; D001374:Azacitidine